Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference
March 01, 2024 09:16 ET
|
Humacyte, Inc.
DURHAM, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
February 29, 2024 21:18 ET
|
Humacyte, Inc.
DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
February 29, 2024 16:01 ET
|
Humacyte, Inc.
DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
February 09, 2024 08:00 ET
|
Humacyte, Inc.
– BLA submission supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a Humanitarian Aid Program to treat wartime trauma injuries in Ukraine – – The HAV...
Humacyte Presents Clinical Performance of Human Acellular Vessel™ (HAV™) From Ukrainian Humanitarian Program
August 15, 2023 08:00 ET
|
Humacyte, Inc.
-Clinical outcomes presented at Military Health System Research Symposium (MHSRS)- -Results will be included in Biologics License Application (BLA) planned for fourth quarter 2023- DURHAM, N.C.,...
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 14, 2023
August 07, 2023 08:00 ET
|
Humacyte, Inc.
DURHAM, N.C., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel™ (HAV™)
August 03, 2023 08:00 ET
|
Humacyte, Inc.
Results published in Journal of Vascular Surgery – Vascular Science DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company...
Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) for Vascular Trauma Repair
July 26, 2023 08:00 ET
|
Humacyte, Inc.
-Top-line results planned to be released in third quarter 2023- -Trial results are intended to support Biologics License Application (BLA) planned for fourth quarter 2023- DURHAM, N.C., July ...
Humacyte to Present at the Jefferies Healthcare Conference
June 05, 2023 16:05 ET
|
Humacyte, Inc.
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable...
Humacyte First Quarter 2023 Financial Results and Business Update
May 12, 2023 07:05 ET
|
Humacyte, Inc.
- Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma - - Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stage...